Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics develops, manufactures and markets specialty plasma-derived biologics, with news centered on its immune globulin portfolio led by ASCENIV and BIVIGAM. Company updates commonly cover FDA label and post-marketing developments for ASCENIV, primary humoral immunodeficiency indications, product revenue trends, U.S. immune globulin market conditions, and distribution arrangements.
Recurring announcements also address plasma collection and biomanufacturing operations, commercial expansion, cash generation, share repurchases, capital-structure priorities and pipeline updates such as SG-001. ADMA's business updates link manufacturing yield, raw plasma supply, distributor inventory and product demand to its financial results.
ADMA Biologics (ADMA) announced key corporate achievements aimed at improving its supply chain and production capacity. The company successfully manufactured three BIVIGAM® conformance batches at a larger plasma volume, anticipates quicker market turnaround, and has installed a new aseptic filling machine to enhance production capabilities. These initiatives are expected to streamline operations and reduce costs, aligning with ADMA's objectives for 2020. Additionally, construction is underway for new plasma collection centers in Tennessee, further supporting their production needs.
Summary not available.